Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer

Molecular Oncology

Volumn 9, Issue 4, 2015, Pages 906-919

  Elbaz, Mohamad ^a,b   Nasser, Mohd W ^a,b   Ravi, Janani ^a,b   Wani, Nissar A ^a,b   Ahirwar, Dinesh K ^a,b   Zhao, Helong ^a,b   Oghumu, Steve ^a,b   Satoskar, Abhay R ^a,b   Shilo, Konstantin ^a,b   Carson, William E ^a,b   Ganju, Ramesh K ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cannabidiol; EGFR; Triple negative breast cancer; Tumor microenvironment

Indexed keywords

CANNABIDIOL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTINEOPLASTIC AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING CELL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; LUNG TUMOR; METABOLISM; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANNABIDIOL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LUNG NEOPLASMS; MACROPHAGES; MICE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84926410281     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.12.010     Document Type: Article

References (57)

1. Biswas D.K., Iglehart J.D. Linkage between EGFR family receptors and nuclear factor kappaB (NF-κB) signaling in breast cancer. J.Cell. Physiol. 2006, 209:645-652.
2. Bosch A., Eroles P., Zaragoza R., Viña J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat. Rev. 2010, 36:206-215.
3. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8:235-244.
4. Capdevila J., Elez E., Macarulla T., Ramos F.J., Ruiz-Echarri M., Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat. Rev. 2009, 35:354-363.
5. Condeelis J., Pollard J. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006 Jan 27, 124(2):263-266.
6. Dijkgraaf E.M., Heusinkveld M., Tummers B., Vogelpoel L.T., Goedemans R., Jha V., Nortier J.W., Welters M.J., Kroep J.R., van der Burg S.H. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013, 73:2480-2492.
7. Eckhardt B.L., Parker B.S., van Laar R.K., Restall C.M., Natoli A.L., Tavaria M.D., Stanley K.L., Sloan E.K., Moseley J.M., Anderson R.L. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix1 1 Department of Defense Breast Cancer Research Program grants DAMD17-98-1-8144 (RL Anderson) and DAMD17-01-1-0371 (MD Tavaria), Susan G. Komen Breast Cancer Foundation predoctoral fellowship (EK Sloan), and NIH/National Cancer Institute grant ROI CA90291 (RL Anderson). Mol. Cancer Res. 2005, 3:1-13.
8. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374.
9. Gazinska P., Grigoriadis A., Brown J.P., Millis R.R., Mera A., Gillett C.E., Holmberg L.H., Tutt A.N., Pinder S.E. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod. Pathol. 2013, 26:955-966.
10. Gil-Bernabé A.M., Ferjančič Š., Tlalka M., Zhao L., Allen P.D., Im J.H., Watson K., Hill S.A., Amirkhosravi A., Francis J.L. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012, 119:3164-3175.
11. Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A. Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics 2012, 13:619.
12. Helbig G., Christopherson K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., Broxmeyer H.E., Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J.Biol. Chem. 2003, 278:21631-21638.
13. Huber M.A., Azoitei N., Baumann B., Grünert S., Sommer A., Pehamberger H., Kraut N., Beug H., Wirth T. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J.Clin. Invest. 2004, 114:569-581.
14. Jacob A., Jing J., Lee J., Schedin P., Gilbert S.M., Peden A.A., Junutula J.R., Prekeris R. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells. J.Cel. Sci. 2013, 126:4647-4658.
15. Jin L., Lim M., Zhao S., Sano Y., Simone B.A., Savage J.E., Wickstrom E., Camphausen K., Pestell R.G., Simone N.L. The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~ 92 cluster. Breast Cancer Res. Treat. 2014, 1-10.
16. Jin U.-H., Lee S.-O., Pfent C., Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer 2014, 14:498.
17. Kim S., Choi J.H., Lim H.I., Lee S.-K., Kim W.W., Cho S., Kim J.S., Kim J.-H., Choe J.-H., Nam S.J. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell Signal. 2009, 21:892-898.
18. Lelekakis M., Moseley J.M., Martin T.J., Hards D., Williams E., Ho P., Lowen D., Javni J., Miller F.R., Slavin J. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 1999, 17:163-170.
19. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J.Pharmacol. Exp. Ther. 2006, 318:1375-1387.
20. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
21. Marcu J.P., Christian R.T., Lau D., Zielinski A.J., Horowitz M.P., Lee J., Pakdel A., Allison J., Limbad C., Moore D.H. Cannabidiol enhances the inhibitory effects of δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 2010, 9:180-189.
22. Massi P., Solinas M., Cinquina V., Parolaro D. Cannabidiol as potential anticancer drug. Br. J. Clin. Pharmacol. 2013, 75:303-312.
23. McAllister S.D., Christian R.T., Horowitz M.P., Garcia A., Desprez P.-Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther. 2007, 6:2921-2927.
24. McAllister S.D., Murase R., Christian R.T., Lau D., Zielinski A.J., Allison J., Almanza C., Pakdel A., Lee J., Limbad C. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res. Treat. 2011, 129:37-47.
25. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., Ponomarev V., Gerald W.L., Blasberg R., Massagué J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J.Clin. Invest. 2005, 115:44-55.
26. Nasser M.W., Qamri Z., Deol Y.S., Ravi J., Powell C.A., Trikha P., Schwendener R.A., Bai X.-F., Shilo K., Zou X. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res. 2012, 72:604-615.
27. Nasser M.W., Qamri Z., Deol Y.S., Smith D., Shilo K., Zou X., Ganju R.K. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PloS One 2011, 6:e23901.
28. Nogi H., Kobayashi T., Suzuki M., Tabei I., Kawase K., Toriumi Y., Fukushima H., Uchida K. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol. Rep. 2009, 21:413-417.
29. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T., Gu K., Shah V., Pei L., Zarbo R.J. NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 2006, 13:62-69.
30. Park H.S., Jang M.H., Kim E.J., Kim H.J., Lee H.J., Kim Y.J., Kim J.H., Kang E., Kim S.-W., Kim I.A. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 2014, 27(9):1212-1222.
31. Pei X.F., Noble M.S., Davoli M.A., Rosfjord E., Tilli M.T., Furth P.A., Russell R., Johnson M.D., Dickson R.B. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. InVitro Cell Dev. Biol. Anim. 2004, 40:14-21.
32. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
33. Pisanti S., Malfitano A.M., Grimaldi C., Santoro A., Gazzerro P., Laezza C., Bifulco M. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:117-131.
34. Place A.E., Jin Huh S., Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011, 13:227.
35. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
36. Preet A., Qamri Z., Nasser M.W., Prasad A., Shilo K., Zou X., Groopman J.E., Ganju R.K. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of Non-Small cell lung Cancer growth and metastasis. Cancer Prev. Res. 2011, 4:65-75.
37. Qamri Z., Preet A., Nasser M.W., Bass C.E., Leone G., Barsky S.H., Ganju R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol. Cancer Ther. 2009, 8:3117-3129.
38. Ravi J., Sneh A., Shilo K., Nasser M.W., Ganju R.K. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 2014, 5(9):2475-2486.
39. Schedin P., O'Brien J., Rudolph M., Stein T., Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J.Mammary Gland Biol. Neoplasia 2007, 12:71-82.
40. Seshacharyulu P., Ponnusamy M.P., Haridas D., Jain M., Ganti A.K., Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:15-31.
41. Shrivastava A., Kuzontkoski P.M., Groopman J.E., Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol. Cancer Ther. 2011, 10:1161-1172.
42. Singel S.M., Batten K., Cornelius C., Jia G., Fasciani G., Barron S.L., Wright W.E., Shay J.W. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res. 2014, 16:R28.
43. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000, 415-433. Elsevier.
44. Su S., Liu Q., Chen J., Chen J., Chen F., He C., Huang D., Wu W., Lin L., Huang W. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014, 25:605-620.
45. Tanaka K., Babic I., Nathanson D., Akhavan D., Guo D., Gini B., Dang J., Zhu S., Yang H., De Jesus J. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 2011, 1:524-538.
46. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
47. Wani N.A., Nasser M.W., Ahirwar D.K., Zhao H., Miao Z., Shilo K., Ganju R.K. CXC motif chemokine 12/CXC chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res. 2014, 16:R54.
48. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010, 7:493-507.
49. Wu Y., Li Y.-Y., Matsushima K., Baba T., Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J.Immunol. 2008, 181:6384-6393.
50. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., Graf T., Pollard J.W., Segall J., Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64:7022-7029.
51. Xie H., Pallero M.A., Gupta K., Chang P., Ware M.F., Witke W., Kwiatkowski D.J., Lauffenburger D.A., Murphy-Ullrich J.E., Wells A. EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCgamma signaling pathway. J.Cel. Sci. 1998, 111:615-624.
52. Xu J.-W., Li Q.-Q., Tao L.-L., Cheng Y.-Y., Yu J., Chen Q., Liu X.-P., Xu Z.-D. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int. J. Oncol. 2011, 39:1501.
53. Yamaguchi H., Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim. Biophys. Acta (BBA)-Molecular Cell Res. 2007, 1773:642-652.
54. Yamaguchi H., Wyckoff J., Condeelis J. Cell migration in tumors. Curr. Opin. Cel. Biol. 2005, 17:559-564.
55. Yu K.-D., Zhu R., Zhan M., Rodriguez A.A., Yang W., Wong S., Makris A., Lehmann B.D., Chen X., Mayer I. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin. Cancer Res. 2013, 19:2723-2733.
56. Zhang H., Berezov A., Wang Q., Zhang G., Drebin J., Murali R., Greene M.I. ErbB receptors: from oncogenes to targeted cancer therapies. J.Clin. Invest. 2007, 117:2051-2058.
57. Zhu X., Mulcahy L.A., Mohammed R., Lee A., Franks H.A., Kilpatrick L., Yilmazer A., Paish E.C., Ellis I.O., Patel P.M. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008, 10:R95.